WO2008003103A3 - Novel multivalent immunoglobulins - Google Patents

Novel multivalent immunoglobulins Download PDF

Info

Publication number
WO2008003103A3
WO2008003103A3 PCT/AT2007/000313 AT2007000313W WO2008003103A3 WO 2008003103 A3 WO2008003103 A3 WO 2008003103A3 AT 2007000313 W AT2007000313 W AT 2007000313W WO 2008003103 A3 WO2008003103 A3 WO 2008003103A3
Authority
WO
WIPO (PCT)
Prior art keywords
immunoglobulin
epitope
novel multivalent
surface molecules
cell surface
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/AT2007/000313
Other languages
German (de)
French (fr)
Other versions
WO2008003103A2 (en
Inventor
Florian Ruecker
Gottfried Himmler
Gordana Wozniak-Knopp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Star Biotechnologische Forschungs und Entwicklungsges mbH
Original Assignee
F Star Biotechnologische Forschungs und Entwicklungsges mbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2009516813A priority Critical patent/JP5924751B2/en
Priority to DK07718518.9T priority patent/DK2046831T3/en
Priority to ES07718518T priority patent/ES2380127T3/en
Priority to AT07718518T priority patent/ATE540056T1/en
Priority to PL07718518T priority patent/PL2046831T3/en
Priority to US12/307,578 priority patent/US20100048877A1/en
Priority to EP07718518A priority patent/EP2046831B1/en
Application filed by F Star Biotechnologische Forschungs und Entwicklungsges mbH filed Critical F Star Biotechnologische Forschungs und Entwicklungsges mbH
Publication of WO2008003103A2 publication Critical patent/WO2008003103A2/en
Publication of WO2008003103A3 publication Critical patent/WO2008003103A3/en
Anticipated expiration legal-status Critical
Priority to US15/677,667 priority patent/US11827720B2/en
Priority to US18/521,492 priority patent/US20240150495A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/005—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies constructed by phage libraries
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention provides a multivalent immunoglobulin or part thereof binding specifically to at least two cell surface molecules of a single cell with at least one modification in at least one structural loop region of said immunoglobulin determining binding to an epitope of said cell surface molecules wherein the unmodified immunoglobulin does not significantly bind to said epitope, its use and methods for producing it .
PCT/AT2007/000313 2006-07-05 2007-06-26 Novel multivalent immunoglobulins Ceased WO2008003103A2 (en)

Priority Applications (9)

Application Number Priority Date Filing Date Title
DK07718518.9T DK2046831T3 (en) 2006-07-05 2007-06-26 New multivalent immunoglobulins
ES07718518T ES2380127T3 (en) 2006-07-05 2007-06-26 New multivalent immunologies
AT07718518T ATE540056T1 (en) 2006-07-05 2007-06-26 NEW MULTIVALENT IMMUNOGLOBULINS
PL07718518T PL2046831T3 (en) 2006-07-05 2007-06-26 Novel multivalent immunoglobulins
US12/307,578 US20100048877A1 (en) 2006-07-05 2007-06-26 Novel multivalent immunoglobulins
JP2009516813A JP5924751B2 (en) 2006-07-05 2007-06-26 Novel multivalent immunoglobulin
EP07718518A EP2046831B1 (en) 2006-07-05 2007-06-26 Novel multivalent immunoglobulins
US15/677,667 US11827720B2 (en) 2006-07-05 2017-08-15 Multivalent immunoglobulins
US18/521,492 US20240150495A1 (en) 2006-07-05 2023-11-28 Novel Multivalent Immunoglobulins

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AT0114706A AT503889B1 (en) 2006-07-05 2006-07-05 MULTIVALENT IMMUNE LOBULINE
ATA1147/2006 2006-07-05

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/307,578 A-371-Of-International US20100048877A1 (en) 2006-07-05 2007-06-26 Novel multivalent immunoglobulins
US15/677,667 Continuation US11827720B2 (en) 2006-07-05 2017-08-15 Multivalent immunoglobulins

Publications (2)

Publication Number Publication Date
WO2008003103A2 WO2008003103A2 (en) 2008-01-10
WO2008003103A3 true WO2008003103A3 (en) 2008-04-17

Family

ID=38720179

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/AT2007/000313 Ceased WO2008003103A2 (en) 2006-07-05 2007-06-26 Novel multivalent immunoglobulins

Country Status (12)

Country Link
US (3) US20100048877A1 (en)
EP (2) EP2046831B1 (en)
JP (3) JP5924751B2 (en)
CN (3) CN101522712A (en)
AT (2) AT503889B1 (en)
DK (2) DK2046831T3 (en)
ES (2) ES2380127T3 (en)
HU (1) HUE025035T2 (en)
PL (2) PL2463302T3 (en)
PT (2) PT2046831E (en)
SI (2) SI2046831T1 (en)
WO (1) WO2008003103A2 (en)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11648308B2 (en) 2016-05-03 2023-05-16 Kymab Limited Methods, regimens, combinations and antagonists
US11878048B2 (en) 2017-06-14 2024-01-23 Kymab Limited Use of the extracellular domain of transferrin receptor 2 for the diagnosis and treatment of primary or secondary sclerosing diseases
US12617872B2 (en) 2025-09-16 2026-05-05 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications

Families Citing this family (129)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3261856B2 (en) 1994-04-12 2002-03-04 東レ株式会社 Melt spinning method
EP1699826B1 (en) 2005-01-05 2009-03-11 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
AT503889B1 (en) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F MULTIVALENT IMMUNE LOBULINE
AT503902B1 (en) * 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw METHOD FOR MANIPULATING IMMUNE LOBULINS
PL2185589T3 (en) 2007-06-01 2016-09-30 Immunoglobulin Fc constant region receptor binding agents
ES2627223T3 (en) 2007-06-26 2017-07-27 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H Presentation of binding agents
EP2535349A1 (en) 2007-09-26 2012-12-19 UCB Pharma S.A. Dual specificity antibody fusions
US8557242B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute ERBB2 antibodies comprising modular recognition domains
KR101658247B1 (en) 2008-01-03 2016-09-22 더 스크립스 리서치 인스티튜트 Antibody targeting through a modular recognition domain
US8454960B2 (en) 2008-01-03 2013-06-04 The Scripps Research Institute Multispecific antibody targeting and multivalency through modular recognition domains
US8574577B2 (en) 2008-01-03 2013-11-05 The Scripps Research Institute VEGF antibodies comprising modular recognition domains
US8557243B2 (en) 2008-01-03 2013-10-15 The Scripps Research Institute EFGR antibodies comprising modular recognition domains
CN101977932B (en) * 2008-01-31 2014-09-03 美国政府健康及人类服务部 Engineered antibody constant domain molecules
EP2113255A1 (en) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
CA2737241C (en) 2008-09-26 2017-08-29 Ucb Pharma S.A. Multivalent antibody fusion proteins
CN102471375A (en) * 2009-07-09 2012-05-23 F-斯塔生物技术研究和发展有限公司 Stabilized immunoglobulin constant domains
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
EP2407487A1 (en) 2010-07-14 2012-01-18 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Multispecific modular antibody
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
TWI542597B (en) 2010-07-28 2016-07-21 吉林尼克公司 Fusion proteins of natural human protein fragments to create orderly multimerized immunoglobulin fc compositions
AU2011283694B2 (en) 2010-07-29 2017-04-13 Xencor, Inc. Antibodies with modified isoelectric points
EP3974453A3 (en) 2010-11-16 2022-08-03 Amgen Inc. Agents and methods for treating diseases that correlate with bcma expression
WO2012109553A2 (en) 2011-02-11 2012-08-16 Research Corporation Technologies Ch2 domain template molecules derived from rational grafting of donor loops onto ch2 scaffolds
EP2714738B1 (en) 2011-05-24 2018-10-10 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
TWI687439B (en) 2011-06-30 2020-03-11 中外製藥股份有限公司 Heterodimerized polypeptide
EP2546268A1 (en) 2011-07-13 2013-01-16 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Internalising immunoglobulin
NO2748201T3 (en) * 2011-08-23 2018-05-12
US12466897B2 (en) 2011-10-10 2025-11-11 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
US10851178B2 (en) 2011-10-10 2020-12-01 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications
WO2013112986A1 (en) * 2012-01-27 2013-08-01 Gliknik Inc. Fusion proteins comprising igg2 hinge domains
JP6628966B2 (en) * 2012-06-14 2020-01-15 中外製薬株式会社 Antigen binding molecule containing an altered Fc region
US9683044B2 (en) 2012-08-20 2017-06-20 Gliknik Inc. Molecules with antigen binding and polyvalent FC gamma receptor binding activity
ES2876009T3 (en) 2012-12-27 2021-11-11 Chugai Pharmaceutical Co Ltd Heterodimerized polypeptide
US9701759B2 (en) 2013-01-14 2017-07-11 Xencor, Inc. Heterodimeric proteins
US10968276B2 (en) 2013-03-12 2021-04-06 Xencor, Inc. Optimized anti-CD3 variable regions
US10131710B2 (en) 2013-01-14 2018-11-20 Xencor, Inc. Optimized antibody variable regions
US10487155B2 (en) 2013-01-14 2019-11-26 Xencor, Inc. Heterodimeric proteins
US11053316B2 (en) 2013-01-14 2021-07-06 Xencor, Inc. Optimized antibody variable regions
KR102211837B1 (en) 2013-01-14 2021-02-03 젠코어 인코포레이티드 Novel heterodimeric proteins
US9605084B2 (en) 2013-03-15 2017-03-28 Xencor, Inc. Heterodimeric proteins
WO2014113510A1 (en) 2013-01-15 2014-07-24 Xencor, Inc. Rapid clearance of antigen complexes using novel antibodies
EP2970486B1 (en) 2013-03-15 2018-05-16 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
US10106624B2 (en) 2013-03-15 2018-10-23 Xencor, Inc. Heterodimeric proteins
US10858417B2 (en) 2013-03-15 2020-12-08 Xencor, Inc. Heterodimeric proteins
US10150800B2 (en) 2013-03-15 2018-12-11 Zyngenia, Inc. EGFR-binding modular recognition domains
KR102813659B1 (en) 2013-11-11 2025-05-28 추가이 세이야쿠 가부시키가이샤 Antigen-binding molecule containing modified antibody variable region
EP3699195A3 (en) 2014-03-28 2020-11-04 Xencor, Inc. Bispecific antibodies that bind to cd38 and cd3
EA035419B9 (en) 2014-05-29 2020-08-07 Мэкроудженикс, Инк. Tri-specific binding molecules and methods of use thereof
TWI693232B (en) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 Covalently bonded diabodies having immunoreactivity with pd-1 and lag-3, and methods of use thereof
PL3180363T3 (en) 2014-08-15 2020-02-28 Merck Patent Gmbh Sirp-alpha immunoglobulin fusion proteins
MX375669B (en) 2014-09-26 2025-03-06 Macrogenics Inc Bispecific monovalent diabodies that are capable of binding CD19 and CD3, and their uses.
TWI831044B (en) 2014-11-11 2024-02-01 日商中外製藥股份有限公司 Antigen-binding molecules, pharmaceutical compositions containing antigen-binding molecules, and methods of manufacturing and selecting antigen-binding molecules
US10259887B2 (en) 2014-11-26 2019-04-16 Xencor, Inc. Heterodimeric antibodies that bind CD3 and tumor antigens
PE20171324A1 (en) 2014-11-26 2017-09-11 Xencor Inc HETERODIMERIC ANTIBODIES THAT BIND CD3 AND TUMOR ANTIGENS
EP3223907A2 (en) 2014-11-26 2017-10-04 Xencor, Inc. Heterodimeric antibodies that bind cd3 and cd38
WO2016087650A1 (en) * 2014-12-05 2016-06-09 Merck Patent Gmbh Domain-exchanged antibody
WO2016105450A2 (en) 2014-12-22 2016-06-30 Xencor, Inc. Trispecific antibodies
RU2017129236A (en) 2015-01-26 2019-03-07 Макродженикс, Инк. MULTIValent MOLECULES CONTAINING DR5-BINDING DOMAINS
US10227411B2 (en) 2015-03-05 2019-03-12 Xencor, Inc. Modulation of T cells with bispecific antibodies and FC fusions
TWI773646B (en) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 Lag-3-binding molecules and methods of use thereof
KR20250053203A (en) 2015-07-24 2025-04-21 글리크닉 인코포레이티드 Fusion proteins of human protein fragments to create orderly multimerized immunoglobulin fc compositions with enhanced complement binding
HUE068868T2 (en) 2015-07-30 2025-02-28 Macrogenics Inc Pd-1-binding molecules and methods of use thereof
BR112018006817A2 (en) 2015-10-08 2018-10-23 Macrogenics Inc cancer treatment method
CA3007030A1 (en) 2015-12-07 2017-06-15 Xencor, Inc. Heterodimeric antibodies that bind cd3 and psma
IL260021B (en) 2015-12-14 2022-09-01 Macrogenics Inc Bispecific molecules having immunoreactivity with pd-1 and ctla-4, and methods of use thereof
WO2017142928A1 (en) 2016-02-17 2017-08-24 Macrogenics, Inc. Ror1-binding molecules, and methods of use thereof
GEP20227398B (en) 2016-04-15 2022-07-25 Macrogenics Inc Novel b7-h3 binding molecules, antibody drug conjugates thereof and usage thereof
AU2017279538A1 (en) 2016-06-07 2019-01-03 Gliknik Inc. Cysteine-optimized stradomers
JP7010854B2 (en) 2016-06-14 2022-01-26 ゼンコア インコーポレイテッド Bispecific checkpoint inhibitor antibody
SG11201811184UA (en) 2016-06-20 2019-01-30 F Star Beta Ltd Lag -3 binding members
RU2769282C2 (en) 2016-06-20 2022-03-30 Кимаб Лимитед Anti-pd-l1 and il-2 cytokines
CN109715663B (en) 2016-06-28 2022-11-25 Xencor股份有限公司 Heterodimeric antibodies binding to somatostatin receptor 2
US11858996B2 (en) 2016-08-09 2024-01-02 Kymab Limited Anti-ICOS antibodies
US10793632B2 (en) 2016-08-30 2020-10-06 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
MY203000A (en) 2016-10-14 2024-06-01 Xencor Inc Il15/il15r� heterodimeric fc-fusion proteins
MX2019006573A (en) 2016-12-09 2019-11-18 Gliknik Inc MANUFACTURING OPTIMIZATION OF GL-2045 A MULTIMERIZING STRADOMER.
CN110022898B (en) 2016-12-09 2023-07-04 格利克尼克股份有限公司 Methods of treating inflammatory diseases with multivalent Fc compounds
CA3048211A1 (en) 2016-12-23 2018-06-28 Macrogenics, Inc. Adam9-binding molecules, and methods of use thereof
US11680101B2 (en) 2017-01-27 2023-06-20 Kymab Limited Anti-OPG antibodies
CN110506055A (en) 2017-02-17 2019-11-26 戴纳立制药公司 Engineered TfR combination polypeptide
AU2018224094B2 (en) 2017-02-24 2025-04-17 Macrogenics, Inc. Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
GB201709970D0 (en) 2017-06-22 2017-08-09 Kymab Ltd Bispecific antigen-binding molecules
WO2019006472A1 (en) 2017-06-30 2019-01-03 Xencor, Inc. Targeted heterodimeric fc fusion proteins containing il-15/il-15ra and antigen binding domains
ES3052814T3 (en) 2017-07-31 2026-01-14 Univ Tokyo Super versatile method for presenting cyclic peptide on protein structure
CR20200129A (en) 2017-10-02 2020-08-22 Denali Therapeutics Inc FUSION PROTEINS INCLUDING ENZYMES FROM ENZYME REPLACEMENT THERAPY
US10981992B2 (en) 2017-11-08 2021-04-20 Xencor, Inc. Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
JP2021502100A (en) 2017-11-08 2021-01-28 ゼンコア インコーポレイテッド Bispecific and monospecific antibodies using novel anti-PD-1 sequences
TW201938194A (en) 2017-12-05 2019-10-01 日商中外製藥股份有限公司 Antigen-binding molecule comprising altered antibody variable region binding CD3 and CD137
KR20200098590A (en) 2017-12-12 2020-08-20 마크로제닉스, 인크. Bispecific CD16-binding molecule and its use in disease treatment
IL275426B2 (en) 2017-12-19 2025-03-01 Xencor Inc Engineered FC fusion proteins containing IL-2
GB201721338D0 (en) 2017-12-19 2018-01-31 Kymab Ltd Anti-icos Antibodies
EP3728314A1 (en) 2017-12-19 2020-10-28 Kymab Limited Bispecific antibody for icos and pd-l1
JP7337079B2 (en) 2018-02-15 2023-09-01 マクロジェニクス，インコーポレーテッド Mutant CD3 binding domains and their use in combination therapy for the treatment of disease
CA3096052A1 (en) 2018-04-04 2019-10-10 Xencor, Inc. Heterodimeric antibodies that bind fibroblast activation protein
US10633458B2 (en) 2018-04-10 2020-04-28 Y-Biologics Inc. Cell engaging binding molecules
EP3781598A1 (en) 2018-04-18 2021-02-24 Xencor, Inc. Tim-3 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and tim-3 antigen binding domains
SG11202010163QA (en) 2018-04-18 2020-11-27 Xencor Inc Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
EP3806885A2 (en) 2018-06-13 2021-04-21 Kymab Limited Antagonists and agonists of the transferrin receptor-2 for use in the treatment of diseases of the bone
GB201811410D0 (en) * 2018-07-12 2018-08-29 F Star Beta Ltd OX40 Binding molecules
ES3044118T3 (en) 2018-07-12 2025-11-26 Invox Pharma Ltd Antibody molecules that bind cd137 and ox40
PT3820569T (en) 2018-07-12 2025-01-14 Invox Pharma Ltd Antibody molecules that bind pd-l1 and cd137
GB201811404D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-CD137 Antibodies
GB201811408D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd CD137 Binding Molecules
GB201811403D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Antibody molecules
GB201811450D0 (en) 2018-07-12 2018-08-29 F Star Delta Ltd Mesothelin and CD137 binding molecules
GB201811415D0 (en) 2018-07-12 2018-08-29 F Star Beta Ltd Anti-Mesothelin Anti bodies
GB201815629D0 (en) 2018-09-25 2018-11-07 Kymab Ltd Antagonists
AU2019355971B2 (en) 2018-10-03 2025-05-08 Xencor, Inc. IL-12 heterodimeric Fc-fusion proteins
GB201820687D0 (en) 2018-12-19 2019-01-30 Kymab Ltd Antagonists
IL319262A (en) 2018-12-24 2025-04-01 Sanofi Sa Pseudofab-based multispecific binding proteins
CA3132185A1 (en) 2019-03-01 2020-09-10 Xencor, Inc. Heterodimeric antibodies that bind enpp3 and cd3
GB201905552D0 (en) 2019-04-18 2019-06-05 Kymab Ltd Antagonists
CR20220541A (en) 2020-03-31 2022-11-28 Chugai Pharmaceutical Co Ltd DELTA-LIKE LIGAND 3 (DLL3) DIRECTED MULTI-SPECIFIC ANTIGEN-BINDING MOLECULES AND THEIR USES
WO2021231976A1 (en) 2020-05-14 2021-11-18 Xencor, Inc. Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
GB202007099D0 (en) 2020-05-14 2020-07-01 Kymab Ltd Tumour biomarkers for immunotherapy
EP4175650A1 (en) 2020-07-06 2023-05-10 Kiromic BioPharma, Inc. Mesothelin isoform binding molecules and chimeric pd1 receptor molecules, cells containing the same and uses thereof
CA3192204A1 (en) 2020-08-19 2022-02-24 Xencor, Inc. Anti-cd28 and/or anti-b7h3 compositions
GB202017058D0 (en) 2020-10-27 2020-12-09 Kymab Ltd Antibodies and uses thereof
WO2022108627A1 (en) 2020-11-18 2022-05-27 Kiromic Biopharma, Inc.Kiromic Biopharma, Inc. Gamma-delta t cell manufacturing processes and chimeric pd1 receptor molecules
GB202101125D0 (en) 2021-01-27 2021-03-10 Kymab Ltd Antibodies and uses thereof
US11739144B2 (en) 2021-03-09 2023-08-29 Xencor, Inc. Heterodimeric antibodies that bind CD3 and CLDN6
EP4305065A1 (en) 2021-03-10 2024-01-17 Xencor, Inc. Heterodimeric antibodies that bind cd3 and gpc3
JP2024515303A (en) * 2021-04-19 2024-04-08 ヤンセン バイオテツク，インコーポレーテツド Molecules with engineered antibody constant region variants
GB202107372D0 (en) 2021-05-24 2021-07-07 Petmedix Ltd Animal models and therapeutics molecules
GB202209247D0 (en) 2022-06-23 2022-08-10 Petmedix Ltd Animal models and therapeutic molecules
GB202217978D0 (en) 2022-11-30 2023-01-11 Petmedix Ltd Rodents expressing a common light chain
US20240199761A1 (en) 2022-12-19 2024-06-20 Astrazeneca Ab Treatment of autoimmune disease
CN120813375A (en) 2023-01-30 2025-10-17 凯玛布有限公司 Antibodies to

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294654B1 (en) * 1995-01-19 2001-09-25 Inger Sandlie Modified immunoglobulin molecule incorporating an antigen in a non-CDR loop region
WO2001083525A2 (en) * 2000-05-03 2001-11-08 Amgen Inc. Modified peptides, comprising an fc domain, as therapeutic agents
WO2002032925A2 (en) * 2000-10-16 2002-04-25 Phylos, Inc. Protein scaffolds for antibody mimics and other binding proteins
US20020106370A1 (en) * 1994-05-13 2002-08-08 Donald Leonard Nicholas Cardy Improvements in or relating to peptide delivery
US20050266000A1 (en) * 2004-04-09 2005-12-01 Genentech, Inc. Variable domain library and uses
WO2006036834A2 (en) * 2004-09-24 2006-04-06 Amgen Inc. MODIFIED Fc MOLECULES
EP1699826A1 (en) * 2005-01-05 2006-09-13 Rüker, Florian Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0570027B1 (en) 1984-03-01 1999-12-29 The Board Of Trustees Of The Leland Stanford Junior University T cell receptor-specific for antigen polypeptides and related polynucleotides
US6492107B1 (en) 1986-11-20 2002-12-10 Stuart Kauffman Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
DE229046T1 (en) 1985-03-30 1987-12-17 Marc Genf/Geneve Ballivet METHOD FOR OBTAINING DNA, RNS, PEPTIDES, POLYPEPTIDES OR PROTEINS BY DNA RECOMBINANT METHOD.
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
DE69028713T3 (en) * 1989-12-27 2004-05-13 Centocor, Inc. CHIMERAL IMMUNOGLOBULINE FOR CD4 RECEPTORS
JP3283041B2 (en) * 1990-07-13 2002-05-20 学校法人藤田学園 Artificial antibody
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
ATE414768T1 (en) 1991-04-10 2008-12-15 Scripps Research Inst LIBRARIES OF HETERODIMER RECEPTORS USING PHAGEMIDS
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5395750A (en) 1992-02-28 1995-03-07 Hoffmann-La Roche Inc. Methods for producing proteins which bind to predetermined antigens
EP0640130B1 (en) 1992-05-08 1998-04-15 Creative Biomolecules, Inc. Chimeric multivalent protein analogues and methods of use thereof
US5844094A (en) 1992-09-25 1998-12-01 Commonwealth Scientific And Industrial Research Organization Target binding polypeptide
US5536814A (en) * 1993-09-27 1996-07-16 La Jolla Cancer Research Foundation Integrin-binding peptides
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
US5783186A (en) 1995-12-05 1998-07-21 Amgen Inc. Antibody-induced apoptosis
US6352842B1 (en) 1995-12-07 2002-03-05 Diversa Corporation Exonucease-mediated gene assembly in directed evolution
US6361974B1 (en) * 1995-12-07 2002-03-26 Diversa Corporation Exonuclease-mediated nucleic acid reassembly in directed evolution
US6358709B1 (en) * 1995-12-07 2002-03-19 Diversa Corporation End selection in directed evolution
JP4046354B2 (en) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Immunoglobulin-like domain with increased half-life
US6696251B1 (en) 1996-05-31 2004-02-24 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
WO1998039482A1 (en) 1997-03-07 1998-09-11 Sunol Molecular Corporation Fusion proteins comprising bacteriophage coat protein and a single-chain t cell receptor
US6057098A (en) 1997-04-04 2000-05-02 Biosite Diagnostics, Inc. Polyvalent display libraries
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
DK1071700T3 (en) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glycosylation modification of antibodies to enhance antibody-dependent cellular cytotoxicity
US6180343B1 (en) 1998-10-08 2001-01-30 Rigel Pharmaceuticals, Inc. Green fluorescent protein fusions with random peptides
US6818418B1 (en) 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US6376246B1 (en) * 1999-02-05 2002-04-23 Maxygen, Inc. Oligonucleotide mediated nucleic acid recombination
ES2341217T3 (en) 1999-01-19 2010-06-17 Maxygen, Inc. RECOMBINATION OF NUCLEIC ACIDS MEDIATED BY OLIGONUCLEOTIDES.
AU3391900A (en) * 1999-03-05 2000-09-21 Maxygen, Inc. Encryption of traits using split gene sequences
US6472147B1 (en) 1999-05-25 2002-10-29 The Scripps Research Institute Methods for display of heterodimeric proteins on filamentous phage using pVII and pIX, compositions, vectors and combinatorial libraries
AU779612C (en) 1999-07-02 2005-12-15 Genentech Inc. Peptide compounds that bind HER2
MXPA02005559A (en) 1999-12-06 2004-09-10 Univ Illinois High affinity tcr proteins and methods.
EP1118661A1 (en) 2000-01-13 2001-07-25 Het Nederlands Kanker Instituut T cell receptor libraries
JP2003274960A (en) 2000-02-03 2003-09-30 Japan Science & Technology Corp Soluble T cell receptor protein and method for producing the same
EP1259601A2 (en) 2000-02-22 2002-11-27 Ahuva Nissim Chimeric and tcr phage display libraries, chimeric and tcr reagents and methods of use thereof
AU2001243670A1 (en) 2000-03-20 2001-10-03 Maxygen, Inc. Method for generating recombinant dna molecules in complex mixtures
AU2001261628A1 (en) 2000-05-16 2001-11-26 Euroceltique S.A. Cd28 synthebody for the modulation of immune responses
CA2409991A1 (en) 2000-05-24 2001-11-29 Imclone Systems Incorporated Bispecific immunoglobulin-like antigen binding proteins and method of production
US6406863B1 (en) 2000-06-23 2002-06-18 Genetastix Corporation High throughput generation and screening of fully human antibody repertoire in yeast
AU2001273559A1 (en) 2000-07-18 2002-01-30 Enchira Biotechnology Corporation Methods of ligation mediated chimeragenesis utilizing populations of scaffold and donor nucleic acids
WO2002008293A2 (en) * 2000-07-25 2002-01-31 Immunomedics Inc. Multivalent target binding protein
JP2002058479A (en) 2000-08-14 2002-02-26 Canon Inc Method for obtaining structure-recognition amino acid sequence
WO2002038602A2 (en) 2000-11-08 2002-05-16 Incyte Genomics, Inc. Secreted proteins
GB0029407D0 (en) 2000-12-01 2001-01-17 Affitech As Product
US7083784B2 (en) 2000-12-12 2006-08-01 Medimmune, Inc. Molecules with extended half-lives, compositions and uses thereof
ES2389251T3 (en) 2000-12-19 2012-10-24 Altor Bioscience Corporation Transgenic animals comprising a humanized immune system
IL141539A0 (en) 2001-02-20 2002-03-10 Yeda Res & Dev Dna molecules and cells transfected therewith
US20030082630A1 (en) 2001-04-26 2003-05-01 Maxygen, Inc. Combinatorial libraries of monomer domains
US20030157561A1 (en) 2001-11-19 2003-08-21 Kolkman Joost A. Combinatorial libraries of monomer domains
EP1281757A1 (en) 2001-07-31 2003-02-05 Direvo Biotech AG Method for the production of nucleic acids consisting of stochastically combined parts of source nucleic acids
IL160359A0 (en) 2001-08-31 2004-07-25 Avidex Ltd Soluble t cell receptor
DK2093286T3 (en) 2001-10-01 2013-05-13 Dyax Corp Multi-chain, eukaryotic display vectors and applications thereof
AU2002337954C1 (en) 2001-10-22 2008-10-23 The Scripps Research Institute Integrin targeting compounds
US20040043424A1 (en) 2001-11-15 2004-03-04 Baughn Mariah R Immunoglobulin superfamily proteins
US20050069549A1 (en) * 2002-01-14 2005-03-31 William Herman Targeted ligands
US20040063924A1 (en) 2002-01-28 2004-04-01 Y Tom Tang Secreted proteins
US20030157091A1 (en) 2002-02-14 2003-08-21 Dyax Corporation Multi-functional proteins
EP1476456A4 (en) 2002-02-19 2007-06-20 Syntherica Corp Compositions and methods for surrogate antibody modulation of an immune response and transport
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
EP2298346A3 (en) 2002-03-04 2011-11-16 Imclone LLC Human antibodies specific to kdr and uses thereof
US20040097711A1 (en) 2002-03-12 2004-05-20 Henry Yue Immunoglobulin superfamily proteins
EP1394251A1 (en) 2002-08-23 2004-03-03 Direvo Biotech AG Method for the selective randomization of polynucleotides
CA2501870C (en) 2002-10-09 2013-07-02 Avidex Limited Single chain recombinant t cell receptors
WO2004041863A2 (en) 2002-11-08 2004-05-21 Ablynx N.V. Single domain antibodies directed against interferon- gamma and uses therefor
PT1558643E (en) 2002-11-09 2009-08-24 Immunocore Ltd T cell receptor display
EP1567553A2 (en) 2002-12-03 2005-08-31 Avidex Ltd. Complexes of receptors
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
WO2005005604A2 (en) * 2003-06-30 2005-01-20 Centocor, Inc. Engineered anti-target immunoglobulin derived proteins, compositions, methods and uses
WO2005021595A1 (en) 2003-08-28 2005-03-10 Euro-Celtique S.A. Methods of antibody engineering using antibody display rules
DK1709081T3 (en) * 2004-01-16 2011-06-06 Regeneron Pharma Fusion polypeptides that can activate receptors
EP1737890A2 (en) 2004-03-24 2007-01-03 Xencor, Inc. Immunoglobulin variants outside the fc region
AU2005246073B2 (en) 2004-05-19 2010-10-28 Adaptimmune Limited Method of improving T cell receptors
ATE417065T1 (en) 2004-05-19 2008-12-15 Medigene Ltd HIGH-AFFINITY NY-ESO T-CELL RECEPTOR
GB0411773D0 (en) 2004-05-26 2004-06-30 Avidex Ltd Method for the identification of polypeptides which bind to a given peptide mhc complex or cd 1-antigen complex
DK1771482T3 (en) 2004-07-22 2014-10-20 Genentech Inc HER2 antibody composition
JP2008514685A (en) 2004-10-01 2008-05-08 メディジーン リミテッド T cell receptor containing a non-natural disulfide interchain linkage linked to a therapeutic agent
AU2005335714B2 (en) 2004-11-10 2012-07-26 Macrogenics, Inc. Engineering Fc antibody regions to confer effector function
EP1812574A2 (en) 2004-11-18 2007-08-01 Avidex Limited Soluble bifunctional proteins
GB0425732D0 (en) 2004-11-23 2004-12-22 Avidex Ltd Gamma-delta t cell receptors
GB0503546D0 (en) 2005-02-21 2005-03-30 Hellenic Pasteur Inst Antibody
US8008453B2 (en) 2005-08-12 2011-08-30 Amgen Inc. Modified Fc molecules
AU2007238034A1 (en) * 2006-04-14 2007-10-25 Trubion Pharmaceuticals Inc. Binding proteins comprising immunoglobulin hinge and Fc regions having altered Fc effector functions
AT503889B1 (en) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F MULTIVALENT IMMUNE LOBULINE
AT503902B1 (en) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw METHOD FOR MANIPULATING IMMUNE LOBULINS
EP1975178A1 (en) 2007-03-30 2008-10-01 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Transcytotic modular antibody
ES2627223T3 (en) 2007-06-26 2017-07-27 F-Star Biotechnologische Forschungs- Und Entwicklungsges.M.B.H Presentation of binding agents
CN101977932B (en) 2008-01-31 2014-09-03 美国政府健康及人类服务部 Engineered antibody constant domain molecules
EP2113255A1 (en) 2008-05-02 2009-11-04 f-star Biotechnologische Forschungs- und Entwicklungsges.m.b.H. Cytotoxic immunoglobulin
CN102471375A (en) 2009-07-09 2012-05-23 F-斯塔生物技术研究和发展有限公司 Stabilized immunoglobulin constant domains
US20120010388A1 (en) 2010-04-16 2012-01-12 Gottfried Himmler LeY SPECIFIC BIOTHERAPEUTIC
EP2407487A1 (en) 2010-07-14 2012-01-18 F-Star Biotechnologische Forschungs - und Entwicklungsges. M.B.H. Multispecific modular antibody
US20140087957A1 (en) 2012-09-25 2014-03-27 Marko Vuskovic Methods, assays and kits for cancer diagnosis and screening utilizing glycan-binding and glycan epitopes
GB201317622D0 (en) 2013-10-04 2013-11-20 Star Biotechnology Ltd F Cancer biomarkers and uses thereof

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020106370A1 (en) * 1994-05-13 2002-08-08 Donald Leonard Nicholas Cardy Improvements in or relating to peptide delivery
US6294654B1 (en) * 1995-01-19 2001-09-25 Inger Sandlie Modified immunoglobulin molecule incorporating an antigen in a non-CDR loop region
WO2001083525A2 (en) * 2000-05-03 2001-11-08 Amgen Inc. Modified peptides, comprising an fc domain, as therapeutic agents
WO2002032925A2 (en) * 2000-10-16 2002-04-25 Phylos, Inc. Protein scaffolds for antibody mimics and other binding proteins
US20050266000A1 (en) * 2004-04-09 2005-12-01 Genentech, Inc. Variable domain library and uses
WO2006036834A2 (en) * 2004-09-24 2006-04-06 Amgen Inc. MODIFIED Fc MOLECULES
EP1699826A1 (en) * 2005-01-05 2006-09-13 Rüker, Florian Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ADACHI MASAAKI ET AL: "Interaction between the antigen and antibody is controlled by the constant domains: Normal mode dynamics of the HEL-HyHEL-10 complex", PROTEIN SCIENCE, CAMBRIDGE UNIVERSITY PRESS, CAMBRIDGE, GB, vol. 12, no. 10, October 2003 (2003-10-01), pages 2125 - 2131, XP009092337, ISSN: 0961-8368 *
CORTEZ-RETAMOZO V ET AL: "Efficient tumor targeting by single-domain antibody fragments of camels", INTERNATIONAL JOURNAL OF CANCER, NEW YORK, NY, US, vol. 98, no. 3, 20 March 2002 (2002-03-20), pages 456 - 462, XP002248403, ISSN: 0020-7136 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11648308B2 (en) 2016-05-03 2023-05-16 Kymab Limited Methods, regimens, combinations and antagonists
US11878048B2 (en) 2017-06-14 2024-01-23 Kymab Limited Use of the extracellular domain of transferrin receptor 2 for the diagnosis and treatment of primary or secondary sclerosing diseases
US12617872B2 (en) 2025-09-16 2026-05-05 Xencor, Inc. Heterodimeric human IgG1 polypeptides with isoelectric point modifications

Also Published As

Publication number Publication date
CN110041430A (en) 2019-07-23
JP2017163998A (en) 2017-09-21
ES2380127T3 (en) 2012-05-08
JP2009540837A (en) 2009-11-26
WO2008003103A2 (en) 2008-01-10
SI2046831T1 (en) 2012-03-30
CN101522712A (en) 2009-09-02
PL2046831T3 (en) 2012-06-29
US20100048877A1 (en) 2010-02-25
AT503889B1 (en) 2011-12-15
JP5924751B2 (en) 2016-05-25
EP2463302B1 (en) 2015-04-01
EP2046831B1 (en) 2012-01-04
US20240150495A1 (en) 2024-05-09
EP2463302A1 (en) 2012-06-13
ES2539593T3 (en) 2015-07-02
EP2046831A2 (en) 2009-04-15
JP2013240338A (en) 2013-12-05
JP6215603B2 (en) 2017-10-18
DK2046831T3 (en) 2012-05-29
SI2463302T1 (en) 2015-08-31
ATE540056T1 (en) 2012-01-15
CN110078828A (en) 2019-08-02
AT503889A1 (en) 2008-01-15
HUE025035T2 (en) 2016-01-28
PT2046831E (en) 2012-04-24
JP6681855B2 (en) 2020-04-15
PT2463302E (en) 2015-07-21
US11827720B2 (en) 2023-11-28
PL2463302T3 (en) 2015-08-31
US20180051095A1 (en) 2018-02-22
DK2463302T3 (en) 2015-06-15

Similar Documents

Publication Publication Date Title
WO2008003103A3 (en) Novel multivalent immunoglobulins
IL197459A0 (en) Humanized proteins, including antibodies and methods for producing the same
WO2009070243A3 (en) Wise binding antibodies and epitopes
IL184103A (en) Synthetic immunoglobulin domains with binding properties engineered in regions of the molecule different from the complementarity determining regions
WO2007106744A3 (en) Anti-5t4 antibodies and uses thereof
WO2008121616A3 (en) Antibodies with decreased deamidation profiles
WO2008047134A3 (en) Antibody molecules which bind il-17a and il-17f
WO2009052400A8 (en) Antibodies that bind to mammalian ngal and uses thereof
WO2009131702A3 (en) Antibodies against fcrn and use thereof
WO2009130459A3 (en) Epitopes of il-17a and il-17f and antibodies specific thereto
WO2006121422A3 (en) Antibodies against clostridium difficile toxins and uses thereof
WO2006053301A3 (en) Fc variants with altered binding to fcrn
WO2007095338A3 (en) Functional antibodies
WO2008076379A3 (en) Human antibodies to human delta like ligand 4
WO2007137984A3 (en) Modified humanised anti-interleukin-18 antibodies
IL198379A (en) Humanized antibodies and antibody fragments that specifically bind sphingosine-1-phosphate, nucleic acids encoding the same and compositions and methods for use thereof to treat disease
EP2937361A3 (en) Fc variants with altered binding to fcRn
IL202232A0 (en) Novel rabbit antibody humanization methods and humanized rabbit antibodies
WO2007041635A3 (en) Fc variants with optimized fc receptor binding properties
IL219653A0 (en) Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof
WO2010025400A3 (en) Cross-reactive and bispecific anti-el 17a/f antibodies
WO2008151819A3 (en) Treatment of tumors using specific anti-l1 antibody
WO2009028625A1 (en) Method of binding protein to support using tamavidin
WO2008098917A3 (en) Novel antibodies against igf-ir
WO2008065384A3 (en) Antibodies specific for the complex of interleukin-6 and the interleukin-6 receptor

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780032991.X

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07718518

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2009516813

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 7210/CHENP/2008

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007718518

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: RU

WWE Wipo information: entry into national phase

Ref document number: 12307578

Country of ref document: US